EMA Recommends Extension of Indications for Atezolizumab
New indication concerns a combination with bevacizumab for the treatment of adults with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1397 results
EMA Recommends Extension of Indications for Nivolumab and Ipilimumab
New indication concerns their combination with 2 cycles of platinum-based chemotherapy in first-line treatment of metastatic NSCLC without sensitising EGFR mutation or ALK translocation
EMA Recommends Extension of Indications for Olaparib
New indications concern the maintenance treatment in combination with bevacizumab of ovarian cancer with HRD positive status and monotherapy of mCRPC with BRCA1/2 mutations
No Survival Advantage from Radical Hysterectomy in Patients with Cervical Cancer and Intraoperative Detection of Positive Lymph Node Involvement
Whether women with cervical cancer benefit from completion of radical surgery upon intraoperative determination of N1 positivity had been controversial
Data from a Large Cohort of Patients with mRCC Demonstrate the Feasibility of ctDNA Analysis and High Concordance with Tissue Genomic Analysis
Identification of the most frequently mutated genes in metastatic renal cell carcinoma
Indicators of Outcome Are Identified for Nivolumab Treatment of Patients with Metastatic Clear Cell Renal Cell Carcinoma
Gene signatures and tumour microenvironments were identified that associate with nivolumab outcomes
Early Evaluation of Nutritional Status Is Needed to Provide Nutritional Support and Decrease Risk of Malnutrition, Sarcopenia and Nosocomial Infection in Cancer Patients
Application of the Global Leadership Initiative on Malnutrition criteria
Quantitative Summary of QoL Data Confirms Immune Checkpoint Inhibitor Therapy Is Generally Well-Tolerated
The abundance and heterogeneity of quality of life literature regarding immune checkpoint inhibitors can make patient education difficult
Registry Findings Highlight the Importance of Interdisciplinary Care in Rheumatic irAEs to Improve Patient Outcome Following Immune Checkpoint Inhibitor Therapy
Rheumatic immune-related adverse events resemble classical rheumatic and musculoskeletal diseases with distinct clinical and laboratory characteristics
Nivolumab Shows Promising Activity in Advanced Tumours with Rare Mutations
Data from first clinical study of nivolumab in patients with pathogenic edPOLE mutated MMR-proficient tumours
Pembrolizumab Delivers Clinical Benefit in Selected Histotypes of Rare Sarcoma
The best response in sarcoma patients treated with pembrolizumab was partial response in the AcSé Pembrolizumab study
Promising Preliminary Results Observed with Novel MK-4830 in Patients with Advanced Solid Tumours
MK-4830, an antibody targeting the myeloid-specific ILT4 receptor, shows promise in advanced solid tumours